301 related articles for article (PubMed ID: 6263470)
1. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
Giuliani F; Casazza AM; Di Marco A; Savi G
Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM
Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic activity of ICRF-159 combined with surgery: effects of postsurgical treatment with cyclophosphamide in mice bearing Lewis lung carcinoma lines.
Sava G; Zorzet S; Perissin L
Anticancer Res; 1985; 5(5):511-5. PubMed ID: 4062252
[TBL] [Abstract][Full Text] [Related]
5. Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.
Poster DS; Penta J; Marsoni S; Bruno S; Macdonald JS
Cancer Clin Trials; 1980; 3(4):315-20. PubMed ID: 7000389
[TBL] [Abstract][Full Text] [Related]
6. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
7. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters.
Herman EH; El-Hage AN; Ferrans VJ; Witiak DT
Res Commun Chem Pathol Pharmacol; 1983 May; 40(2):217-31. PubMed ID: 6410471
[TBL] [Abstract][Full Text] [Related]
8. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line.
Wadler S; Green MD; Muggia FM
Cancer Res; 1986 Mar; 46(3):1176-81. PubMed ID: 3080237
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor activity of doxorubicin in the treatment of hemocytoblastosis La and various ascites tumors in mice].
Ul'ianova LA; Tarasova VE; Bazhanov VS; Iudina OI; Gol'dberg LE
Antibiotiki; 1984 Nov; 29(11):861-6. PubMed ID: 6524889
[TBL] [Abstract][Full Text] [Related]
12. Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187.
El-Hage AN; Herman EH; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):509-23. PubMed ID: 7036302
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
Woodman RJ
Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
[No Abstract] [Full Text] [Related]
14. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
15. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
16. ICRF-187 in clinical oncology.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388
[TBL] [Abstract][Full Text] [Related]
17. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
18. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
Marks TA; Venditti JM
Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
[TBL] [Abstract][Full Text] [Related]
20. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Yoshida M; Maehara Y; Sugimachi K
Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]